[go: up one dir, main page]

WO2017070137A1 - Combinaison d'inhibiteurs de ck2 et de modulateurs de points de contrôle immunitaires pour le traitement du cancer - Google Patents

Combinaison d'inhibiteurs de ck2 et de modulateurs de points de contrôle immunitaires pour le traitement du cancer Download PDF

Info

Publication number
WO2017070137A1
WO2017070137A1 PCT/US2016/057584 US2016057584W WO2017070137A1 WO 2017070137 A1 WO2017070137 A1 WO 2017070137A1 US 2016057584 W US2016057584 W US 2016057584W WO 2017070137 A1 WO2017070137 A1 WO 2017070137A1
Authority
WO
WIPO (PCT)
Prior art keywords
chrg
antibody
substituted
cancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/057584
Other languages
English (en)
Inventor
Brent A. Rupnow
Maria Jure-Kunkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of WO2017070137A1 publication Critical patent/WO2017070137A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Definitions

  • This invention relates to methods for treating cancer in a subj ect comprising administering to the subject a combination of a CK2 inhibitor and an immune checkpoint modulator.
  • Cancer takes advantage of this ability to hide from the immune system by exploiting a series of immune escape mechanisms that were developed to avoid autoimmunity. Among these mechanisms are the hijacking of immune-cell- intrinsic checkpoints that are induced on T-cell activation (Pardoll et al, Nat Rev Cancer 2012, 12:252-64).
  • a novel approach in immunotherapy of cancer has been to counteract these resistance mechanisms, activating and allowing the endogenous immune system to reject tumors.
  • CTLA-4 cytotoxic T-lymphocyte-associated antigen 4
  • the Programmed Death 1 receptor is another key checkpoint receptor expressed by activated T and B cells and mediates immunosuppression.
  • PD-1 is a member of the CD28 family of receptors, which includes CD28, CTLA-4, ICOS, PD-1, and BTLA.
  • Two cell surface glycoprotein ligands for PD-1 have been identified, Programmed Death Ligand-1 (PD-L1) and Programmed Death Ligand-2 (PD-L2), that are expressed on antigen-presenting cells as well as many human cancers and have been shown to down-regulate T cell activation and cytokine secretion upon binding to PD-1. Inhibition of the PD-1/PD-L1 interaction mediates potent antitumor activity in preclinical models (U.S.
  • Patent Nos. 8,008,449 and 7,943,743 disclose the use of antibody inhibitors of the PD-1/PD-L1 interaction for treating cancer has entered clinical trials (Brahmer et al, 2010, J Clin Oncol 28:3167-75; Topalian et al., 2012, NEngl JMed 366:2443-54;
  • Protein kinase CK2 (formerly known as casein kinase II) is a highly conserved serine/threonine kinase. Protein kinase CK2 is ubiquitously distributed and constitutively active in eukaryotes. In mammals, the enzyme exists in two isozymic forms due to variations in the catalytic subunits of the enzyme. The CK2 holoenzyme is a
  • CK2A1 catalytic a
  • CK2A2A2 catalytic a subunits
  • CK2A2A2 a' subunits
  • CK2A2 a subunits
  • CK2A2 a subunit of CK2
  • CK2A2 a subunit of CK2
  • CK2A2 catalytic a subunits
  • CK2A2A2 a subunits
  • CK2A2 complexes containing the catalytic subunits requires dimerization of the regulatory ⁇ -subunits.
  • CK2 interacts with a variety of cellular proteins and has been implicated in various cellular processes such as cell proliferation and differentiation, cellular survival, and tumorigenesis. With respect to tumorigenesis, protein kinase CK2 has been implicated in kidney tumors (Stalter et al, "Asymmetric expression of protein kinase CK2 subunits in human kidney tumors", Biochem. Biophys. Res. Comm
  • CK2 inhibitors can act synergistically when used in combination with certain immune checkpoint modulators (ICMs) such as an anti-Programmed Death-1 (PD-1) antibody or an anti-Cytotoxic T-Lymphocyte-associated Antigen 4 (CTLA-4) antibody. It is an object of the invention to provide efficacious immunotherapeutic treatment regimens wherein CK2 inhibitors are combined with ICMs for the treatment of proliferative diseases.
  • ICMs immune checkpoint modulators
  • the present invention provides a method for the treatment of proliferative diseases, including cancer, which comprises administering to a subject in need thereof a synergistically, therapeutically effective amount of (1) a CK2 inhibitor and (2) an ICM.
  • the ICM is selected from an antagonist of CTLA-4, PD-1,
  • PD-L1, PD-L2, LAG-3, TIM-3 Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4.
  • the ICM is selected from an anti-CTLA-4 antibody, i.e. , ipilimumab (also referred to as Yervoy®) and an anti-PD-1 antibody, i.e. nivolumab (also referred to as Opdivo®).
  • an anti-CTLA-4 antibody i.e. , ipilimumab (also referred to as Yervoy®)
  • an anti-PD-1 antibody i.e. nivolumab (also referred to as Opdivo®).
  • the CK2 inhibitor is selected from CX-4945 and CX-8184.
  • the CK2 inhibitor is a compound of Formula (I):
  • R.4 is selected from the group consisting of Ci-4alkyl substituted with 1-3 R e , C3-
  • R7 and R7 together with the nitrogen atom to which they are both attached form a 4- to 7- membered monocyclic or 7- to 12-membered bicyclic heterocycle containing carbon atoms and additional 1-3 heteroatoms selected from the group consisting of NR8a, O, and S(0)2 and substituted with 1-4 Rs;
  • R8 at each occurrence, is independently selected from the group consisting of H, F, CI,
  • R8a is selected from the group consisting of H, Ci-4alkyl substituted with 1-5 R e , C2-4 alkenyl substituted with 1 -5 Re, -(CHRg)rORb, -(CHRg)rS(0)pRc, -
  • Ra at each occurrence, is independently selected from the group consisting of H, CN, Ci-6 alkyl substituted with 1-5 Re, C2-6 alkenyl substituted with 1-5 R e , C2-6 alkynyl substituted with 1-5 R e , -(CH2)r-C3-iocarbocyclyl substituted with 1-5 Re, and - (CH2)r-heterocyclyl substituted with 1-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 1-5 R e ;
  • Rb at each occurrence, is independently selected from the group consisting of H, Ci-6 alkyl substituted with 1-5 Re, C2-6 alkenyl substituted with 1-5 R e , C2-6 alkynyl substituted with 1-5 R e , -(CH2)r-C3-iocarbocyclyl substituted with 1-5 Re, and - (CH2)r-heterocyclyl substituted with 1-5 Re;
  • Rc at each occurrence, is independently selected from the group consisting of Ci-6 alkyl substituted with 1-5 R e , C2-6alkenyl substituted with 1-5 R e , C2-6alkynyl substituted with 1-5 R e , C3-6carbocyclyl, and heterocyclyl;
  • Rd at each occurrence, is independently selected from the group consisting of H, OH, Ci-6 alkyl substituted with 1-5 Re, C2-6alkenyl substituted with 1-5 Re, C2-6alkynyl substituted with 1-5 R e , -(CH2)r-C3-iocarbocyclyl substituted with 1-5 Re, and - (CH2)r-heterocyclyl substituted with 1-5 Re;
  • Rf at each occurrence, is independently selected from the group consisting of H, -
  • R at each occurrence, is independently selected from the group consisting of H, F, OH, and Ci-5alkyl;
  • p at each occurrence, is independently selected from the group consisting of zero, 1, and 2;
  • r at each occurrence, is independently selected from the group consisting of zero, 1, 2, 3, 4, and 5.
  • the present invention further provides a pharmaceutical composition for the synergistic treatment of cancer which comprises at least one CK2 inhibitor and an ICM, and a pharmaceutically acceptable carrier.
  • the ICM is administered simultaneous with or before or after the administration of a compound of Formulas (I) and (II).
  • the present invention provides methods for the scheduled administration of CK2 inhibitors in synergistic combination(s) with immune checkpoint modulators (ICMs) for the treatment and prevention of proliferative diseases.
  • ICMs immune checkpoint modulators
  • the invention provides methods for treating cancer in a patient comprising the administration of a CK2 inhibitor of Formulas (I) and (II) in combination with an anti-PD-1 antibody or an anti-CTLA-4 antibody.
  • anti-PD-1 antibodies include, but are not limited to, nivolumab, pembrolizumab, MEDI-0680, and pidilizumab.
  • anti-CTLA-4 antibodies include, but are not limited to, ipilimumab and tremelimumab.
  • CK2 inhibitors of Formulas (I) and (II) when used in combination with an anti-CTLA-4 antibody or anti-PD-1 antibody demonstrate superior cytotoxic activity.
  • alkyl refers to an unsubstituted alkyl group of 1 to 6, preferably 1 to 4, carbon atoms.
  • aralkyl refers to an aryl group bonded directly through a lower alkyl group.
  • a preferred aralkyl group is benzyl.
  • aryl refers to a monocyclic or bicyclic aromatic hydrocarbon group having 6 to 12 carbon atoms in the ring portion.
  • exemplary of aryl herein are phenyl, naphthyl and biphenyl groups.
  • heterocyclo refers to a fully saturated or unsaturated, aromatic or nonaromatic cyclic group which is a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring system which has at least one heteroatom in at least one carbon atom-containing ring.
  • Each ring of the heterocyclic group containing a heteroatom may have 1 , 2, 3 or 4 heteroatoms selected from nitrogen, oxygen and sulfur where the nitrogen and sulfur heteroatoms may also optionally be oxidized and the nitrogen heteroatoms may also optionally be quaternized.
  • the heterocyclo group may be attached at any heteroatom or carbon atom.
  • Exemplary monocyclic heterocyclo groups include pyrrolidinyl, pyrrolyl, indolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2- oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxazepinyl, azepinyl, 4- piperidonyl, pyridyl, N-oxo-pyridyl,
  • tetrahydrothiopyranyl tetrahydropyranyl
  • morpholinyl thiamorpholinyl
  • thiamorpholinyl sulfoxide tetrahydrothiopyranylsulfone, thiamorpholinyl sulfone, 1 ,3-dioxolane, tetrahydro-l, l-dioxothienyl, dioxanyl, isothiazolidinyl, thietanyl, thiiranyl, triazinyl, triazolyl, and the like.
  • Exemplary bicyclic heterocyclo groups include benzothiazolyl, benzoxazolyl, benzothienyl, quinolinyl, quinolinyl-N-oxide, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3- cjpyridinyl, furo[3,l-b]pyridinyl or furo[2,3-b]pyridinyl), dihydroisoindolyl,
  • dihydroquinazolinyl such as 3,4-dihydro-4-oxo-quinazolinyl
  • benzisothiazolyl benzisoxazolyl
  • benzodiazinyl benzofurazanyl
  • benzothiopyranyl benzotriazolyl
  • benzpyrazolyl dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, dihydrobenzopyranyl, indolinyl, isochromanyl, isoindolinyl, naphthyridinyl, phthalazinyl, piperonyl, purinyl, pyridopyridyl, quinazolinyl, tetrahydroquinolinyl, thienofuryl, thienopyridyl, thienothienyl, and the like.
  • a group When a group is referred to as being optionally substituted, it may be substituted with one to five, preferably one to three, substituents such as F, CI, Br, I, trifluoromethyl, trifluoromethoxy, hydroxy, lower alkoxy, cycloalkoxy, heterocyclooxy, oxo, lower alkanoyl, aryloxy, lower alkanoyloxy, amino, lower alkylamino, arylamino, aralkylamino, cycloalkylamino, heterocycloamino, disubstituted amines in which the two amino substituents independently are selected from lower alkyl, aryl or aralkyl, lower alkanoylamino, aroylamino, aralkanoylamino, substituted lower alkanoylamino, substituted arylamino, substituted aralkylanoylamino, thiol, lower alkylthio, aryl
  • substituted sulfonamide nitro, cyano, carboxy, carbamyl (e.g., CONH2), substituted carbamyl (e.g., CONH-lower alkyl, CONH-aryl, CONH-aralkyl or cases where there are two substituents on the nitrogen independently selected from lower alkyl, aryl or aralkyl), lower alkoxy carbonyl, aryl, substituted aryl, guanidino, and heterocyclos (e.g., indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl and the like).
  • carbamyl e.g., CONH2
  • substituted carbamyl e.g., CONH-lower alkyl, CONH-aryl, CONH-aralkyl or cases where there are two substituents on the nitrogen independently selected from lower alkyl,
  • substitutuent is further substituted, it will be substituted with F, CI, Br, I, optionally substituted lower alkyl, hydroxy, optionally substituted lower alkoxy, optionally substituted aryl, or optionally substituted aralkyl.
  • administering refers to the physical introduction of a composition comprising a therapeutic agent to a subject, using any of the various methods and delivery systems known to those skilled in the art.
  • Preferred routes of administration for the anti-PD-1 antibody and/or the anti-CTLA4 antibody include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion.
  • parenteral administration means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrastemal injection and infusion, as well as in vivo electroporation.
  • the CK2 inhibitor is typically administered via a non-parenteral route, preferably orally.
  • non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically.
  • Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
  • an "adverse event” as used herein is any unfavorable and generally unintended or undesirable sign (including an abnormal laboratory finding), symptom, or disease associated with the use of a medical treatment.
  • an adverse event may be associated with activation of the immune system or expansion of immune system cells (e.g. , T cells) in response to a treatment.
  • a medical treatment may have one or more associated AEs and each AE may have the same or different level of severity.
  • Reference to methods capable of "altering adverse events” means a treatment regime that decreases the incidence and/or severity of one or more AEs associated with the use of a different treatment regime.
  • an “antibody” shall include, without limitation, a glycoprotein
  • immunoglobulin which binds specifically to an antigen and comprises at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or an antigen- binding portion thereof.
  • H chain comprises a heavy chain variable region
  • the heavy chain constant region comprises three constant domains, Cm, Cm and Cm.
  • Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region.
  • the light chain constant region is comprises one constant domain, CL.
  • the YH and YL regions can be further subdivided into regions of hypervariability, termed
  • CDRs complementarity determining regions
  • FR framework regions
  • Each YH and YL comprises three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • the constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
  • An immunoglobulin may derive from any of the commonly known isotypes, including but not limited to IgA, secretory IgA, IgG and IgM.
  • IgG subclasses are also well known to those in the art and include but are not limited to human IgGl, IgG2, IgG3 and IgG4.
  • “Isotype” refers to the Ab class or subclass (e.g. , IgM or IgGl) that is encoded by the heavy chain constant region genes.
  • antibody includes, by way of example, both naturally occurring and non-naturally occurring antibodies; monoclonal and polyclonal antibodies; chimeric and humanized antibodies; human or nonhuman antibodies; wholly synthetic antibodies; and single chain antibodies.
  • a nonhuman Ab may be humanized by recombinant methods to reduce its immunogenicity in man.
  • the term "antibody” also includes an antigen-binding fragment or an antigen-binding portion of any of the aforementioned immunoglobulins, and includes a monovalent and a divalent fragment or portion, and a single chain Ab.
  • an “isolated antibody” refers to an Ab that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated Ab that binds specifically to PD-1 is substantially free of Abs that bind specifically to antigens other than PD-1).
  • an isolated Ab may be substantially free of other cellular material and/or chemicals.
  • mAb monoclonal antibody
  • MAbs refers to a non-naturally occurring preparation of Ab molecules of single molecular composition, i.e., Ab molecules whose primary sequences are essentially identical, and which exhibits a single binding specificity and affinity for a particular epitope.
  • a mAb is an example of an isolated Ab.
  • MAbs may be produced by hybridoma, recombinant, transgenic or other techniques known to those skilled in the art.
  • Human antibody refers to an Ab having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the Ab contains a constant region, the constant region also is derived from human germline immunoglobulin sequences.
  • the human Abs of the invention may include amino acid residues not encoded by human germline
  • immunoglobulin sequences e.g. , mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo.
  • human antibody as used herein, is not intended to include Abs in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
  • a “humanized antibody” refers to an Ab in which some, most or all of the amino acids outside the CDR domains of a non-human Ab are replaced with corresponding amino acids derived from human immunoglobulins. In one embodiment of a humanized form of an Ab, some, most or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulins, whereas some, most or all amino acids within one or more CDR regions are unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they do not abrogate the ability of the Ab to bind to a particular antigen.
  • a "humanized” Ab retains an antigenic specificity similar to that of the original Ab.
  • a “chimeric antibody” refers to an Ab in which the variable regions are derived from one species and the constant regions are derived from another species, such as an Ab in which the variable regions are derived from a mouse Ab and the constant regions are derived from a human Ab.
  • an “anti-antigen” Ab refers to an Ab that binds specifically to the antigen.
  • an anti-PD-1 Ab binds specifically to PD-1 and an anti-CTLA4 Ab binds specifically to CTLA4.
  • An "antigen-binding portion" of an Ab (also called an “antigen-binding fragment”) refers to one or more fragments of an Ab that retain the ability to bind specifically to the antigen bound by the whole Ab.
  • ICM immune checkpoint modulator
  • Checkpoint proteins regulate T-cell activation or function. Numerous checkpoint proteins are known, such as CTLA-4 and its ligands CD80 and CD86; and PD1 with its ligands PDL1 and PDL2 (Pardoll, Nature Reviews Cancer 12: 252-264, 2012). These proteins are responsible for co- stimulatory or inhibitory interactions of T-cell responses. Immune checkpoint proteins regulate and maintain self-tolerance and the duration and amplitude of physiological immune responses. Immune checkpoint modulators include antibodies or are derived from antibodies.
  • cancer refers a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth divide and grow results in the formation of malignant tumors that invade neighboring tissues and may also metastasize to distant parts of the body through the lymphatic system or bloodstream.
  • cancer tumor necrosis
  • tumor tumor necrosis
  • immunotherapy refers to the treatment of a subject afflicted with, or at risk of contracting or suffering a recurrence of, a disease by a method comprising inducing, enhancing, suppressing or otherwise modifying an immune response.
  • Treatment or “therapy” of a subject refers to any type of intervention or process performed on, or the administration of an active agent to, the subject with the objective of reversing, alleviating, ameliorating, inhibiting, slowing down or preventing the onset, progression, development, severity or recurrence of a symptom, complication or condition, or biochemical indicia associated with a disease.
  • PD-1 Programmed Death- 1
  • PD-1 is expressed predominantly on previously activated T cells in vivo, and binds to two ligands, PD-L1 and PD-L2.
  • the term "PD-1” as used herein includes human PD-1 (hPD-1), variants, isoforms, and species homologs of hPD-1, and analogs having at least one common epitope with hPD-1.
  • the complete hPD-1 sequence can be found under GenBank Accession No. U64863.
  • the terms "cytotoxic T lymphocyte-associated antigen-4,” “CTLA-4,” “CTLA4,” “CTLA-4 antigen” and "CD152” see, e.g.
  • CTLA-4 Murat m. J. Pathol. (1999) 155:453-460) are used interchangeably, and include variants, isoforms, species homologs of human CTLA-4, and analogs having at least one common epitope with CTLA-4 (see, e.g., Balzano (1992) Int. J. Cancer Suppl. 7:28-32).
  • the complete CTLA-4 nucleic acid sequence can be found under GenBank Accession No. L15006.
  • a “subject” includes any human or nonhuman animal.
  • nonhuman animal includes, but is not limited to, vertebrates such as nonhuman primates, sheep, dogs, and rodents such as mice, rats and guinea pigs.
  • the subject is a human.
  • the terms, "subject” and “patient” are used interchangeably herein.
  • a “therapeutically effective amount” or “therapeutically effective dosage” of a drug or therapeutic agent is any amount of the drug that, when used alone or in combination with another therapeutic agent, protects a subject against the onset of a disease or promotes disease regression evidenced by a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction.
  • the ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.
  • an “anti-cancer agent” promotes cancer regression in a subject.
  • a therapeutically effective amount of the drug promotes cancer regression to the point of eliminating the cancer.
  • “Promoting cancer regression” means that administering an effective amount of the drug, alone or in combination with an anti-neoplastic agent, results in a reduction in tumor growth or size, necrosis of the tumor, a decrease in severity of at least one disease symptom, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction.
  • the terms “effective” and “effectiveness” with regard to a treatment includes both pharmacological effectiveness and physiological safety.
  • Pharmacological effectiveness refers to the ability of the drug to promote cancer regression in the patient.
  • Physiological safety refers to the level of toxicity, or other adverse physiological effects at the cellular, organ and/or organism level (adverse effects) resulting from administration of the drug.
  • a therapeutically effective amount of an anti-cancer agent preferably inhibits cell growth or tumor growth by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects.
  • tumor regression may be observed and continue for a period of at least about 20 days, more preferably at least about 40 days, or even more preferably at least about 60 days.
  • immunotherapeutic response pattern refers to a clinical response pattern often observed in cancer patients treated with immunotherapeutic agents that produce antitumor effects by inducing cancer-specific immune responses or by modifying native immune processes.
  • This response pattern is characterized by a beneficial therapeutic effect that follows an initial increase in tumor burden or the appearance of new lesions, which in the evaluation of traditional chemotherapeutic agents would be classified as disease progression and would be synonymous with drug failure. Accordingly, proper evaluation of immunotherapeutic agents may require long-term monitoring of the effects of these agents on the target disease.
  • a therapeutically effective amount of a drug includes a "prophylactically effective amount," which is any amount of the drug that, when administered alone or in combination with an anti -neoplastic agent to a subject at risk of developing a cancer (e.g., a subject having a pre-malignant condition) or of suffering a recurrence of cancer, inhibits the development or recurrence of the cancer.
  • the prophylactically effective amount prevents the development or recurrence of the cancer entirely. “Inhibiting" the development or recurrence of a cancer means either lessening the likelihood of the cancer's development or recurrence, or preventing the development or recurrence of the cancer entirely.
  • any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.
  • CK2 has been shown to be associated with acute and chronic myelogenous leukemia, lymphoma and multiple myeloma.
  • enhanced CK2 activity has been observed in solid tumors of the colon, rectum and breast, squamous cell carcinomas of the lung and of the head and neck (SCCHN), adenocarcinomas of the lung, colon, rectum, kidney, breast, and prostate.
  • Inhibition of CK2 by a small molecule is reported to induce apoptosis of pancreatic cancer cells, and hepatocellular carcinoma cells (HegG2, Hep3, HeLa cancer cell lines); and CK2 inhibitors dramatically sensitized RMS
  • CK2 (Rhabdomyosarcoma) tumors toward apoptosis induced by TRAIL.
  • an inhibitor of CK2 alone, or in combination with another anti-cancer agent, would be useful to treat cancer.
  • the CK2 inhibitor for use in the methods of the invention is a compound of Formula (I):
  • R4 is selected from the group consisting of Ci-4alkyl substituted with 1-3 R e , C3- 6cycloalkyl and heterocyclyl substituted with 1-3 R e ; Rj and R7 together with the nitrogen atom to which they are both attached form a 4- to 7- membered monocyclic or 7- to 12-membered bicyclic heterocycle containing carbon atoms and additional 1-3 heteroatoms selected from the group consisting of NR8a, O, and S(0)2 and substituted with 1-4 Rs;
  • Ra at each occurrence, is independently selected from the group consisting of H, CN, Ci-6 alkyl substituted with 1-5 Re, C2-6 alkenyl substituted with 1-5 R e , C2-6 alkynyl substituted with 1-5 R e , -(CH2)r-C3-iocarbocyclyl substituted with 1-5 Re, and - (CH2)r-heterocyclyl substituted with 1-5 Re; or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 1-5 R e ;
  • Rb at each occurrence, is independently selected from the group consisting of H, Ci-6 alkyl substituted with 1-5 Re, C2-6 alkenyl substituted with 1-5 R e , C2-6 alkynyl substituted with 1-5 R e , -(CH2)r-C3-iocarbocyclyl substituted with 1-5 Re, and - (CH2)r-heterocyclyl substituted with 1-5 Re;
  • Rc at each occurrence, is independently selected from the group consisting of Ci-6 alkyl substituted with 1-5 R e , C2-6alkenyl substituted with 1-5 R e , C2-6alkynyl substituted with 1-5 R e , C3-6carbocyclyl, and heterocyclyl;
  • Rd at each occurrence, is independently selected from the group consisting of H, OH, Ci-6 alkyl substituted with 1-5 Re, C2-6alkenyl substituted with 1-5 R e , C2-6alkynyl substituted with 1-5 Re, -(CH2)r-C3-iocarbocyclyl substituted with 1-5 Re, and - (CH2)r-heterocyclyl substituted with 1-5 Re;
  • Rf at each occurrence, is independently selected from the group consisting of H, -
  • R at each occurrence, is independently selected from the group consisting of H, F, OH, and Ci-salkyl;
  • p at each occurrence, is independently selected from the group consisting of zero, 1, and 2; and r, at each occurrence, is independently selected from the group consisting of zero, 1, 2, 3, 4, and 5.
  • the CK2 inhibitor for use in the methods of the invention is a compound of Formula (I) including enantiomers, diastereomers, tautomers, pharmaceutically-acceptable salts, prodrugs, hydrates, or solvates thereof, wherein
  • R.4 is selected from the group consisting of Ci-4alkyl, C3-6cycloalkyl, and heterocyclyl, each substituted with 1-3 Re;
  • R.6c is selected from the group consisting of F and CI;
  • NR7R7 is selected from the group consisting of
  • R8a is selected from the group consisting of H, Ci-4alkyl, S(0) 2 Ci-4alkyl, and 5- to 6-membered heterocyclyl substituted with 1-4 Re.
  • the CK2 inhibitor for use in the methods of the invention is a compound of Formula (I) including enantiomers, diastereomers, tautomers, pharmaceutically-acceptable salts, prodrugs, hydrates, or solvates thereof, wherein
  • R4 is selected from the group consisting of methyl, ethyl, propyl, and cyclopropyl;
  • R6c is CI
  • R6d is selected from the group consisting of CN, OCHF 2 , and CHF 2 ;
  • NR7R7 is selected from the group consisting of
  • n at each occurrence, is independently selected from the group consisting of zero, 1, and 2.
  • the CK2 inhibitor for use in the methods of the invention is a compound of Formula (II):
  • R 4 is selected from the group consisting of methyl, ethyl, propyl, and cyclopropyl;
  • R6c is CI
  • R6d is selected from the group consisting of CN, OCHF2, and CHF2;and m, at each occurrence, is independently selected from the group consisting of zero, 1, and 2.
  • R8 is selected from the group consisting of F, Ci- 4 alkyl substituted with 1-4 R e , -
  • n at each occurrence, is independently selected from the group consisting of zero, 1, and 2.
  • the CK2 inhibitor of Formulas (I) and (II) for use in the methods of the invention is Compound 1 :
  • HuMAbs that bind specifically to PD-1 with high affinity have been disclosed in U.S. Patent No. 8,008,449.
  • Other anti-PD-1 mAbs have been described in, for example, U.S. Patent Nos. 6,808,710, 7,488,802, 8,168,757 and 8,354,509, and PCT Publication No. WO 2012/145493.
  • 8,008,449 has been demonstrated to exhibit one or more of the following characteristics: (a) binds to human PD-1 with a KD of 1 x 10 "7 M or less, as determined by surface plasmon resonance using a Biacore biosensor system; (b) does not substantially bind to human CD28, CTLA-4 or ICOS; (c) increases T-cell proliferation in a Mixed
  • Lymphocyte Reaction MLR assay
  • (d) increases interferon- ⁇ production in an MLR assay
  • (e) increases IL-2 secretion in an MLR assay
  • (f) binds to human PD-1 and cynomolgus monkey PD-1
  • (g) inhibits the binding of PD-L1 and/or PD-L2 to PD-1
  • (h) stimulates antigen-specific memory responses
  • Anti-PD-1 Abs usable in the present invention include mAbs that bind specifically to human PD-1 and exhibit at least one, preferably at least five, of the preceding characteristics.
  • a preferred anti-PD-1 Ab is nivolumab.
  • Nivolumab is a fully human IgG4 anti- PD-1 monoclonal antibody disclosed as 5C4 in WO 2006/121168. Nivolumab is known to augment cellular immune responses against tumors (Brahmer, JR et al, 2010, J Clin Oncol 28:3167-3175).
  • Another anti-PD-1 Ab usable in the present methods is pembrolizumab (Hamid et al, 2013, New England Journal of Medicine 369 (2): 134-44).
  • Anti-PD-1 Abs usable in the disclosed methods also include isolated Abs that bind specifically to human PD-1 and cross-compete for binding to human PD-1 with nivolumab (see, e.g.
  • these anti-PD-1 Abs are preferably chimeric Abs, or more preferably humanized or human Abs. Such chimeric, humanized or human mAbs can be prepared and isolated by methods well known in the art.
  • Anti-PD-1 Abs usable in the methods of the disclosed invention also include antigen-binding portions of the above Abs. It has been amply demonstrated that the antigen-binding function of an Ab can be performed by fragments of a full-length Ab.
  • binding fragments encompassed within the term "antigen-binding portion" of an Ab include (i) a Fab fragment, a monovalent fragment consisting of the YL, YH, CL and Cm domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the YH and Cm domains; and (iv) a Fv fragment consisting of the YL and YH domains of a single arm of an Ab.
  • Anti- PD-1 antibodies (or VH and/or VL domains derived therefrom) suitable for use in the invention can be generated using methods well known in the art.
  • An exemplary anti-PD-1 antibody is nivolumab comprising heavy and light chains comprising the sequences shown in SEQ ID NOs: 11 and 12, respectively, or antigen binding fragments and variants thereof.
  • the antibody has heavy and light chain CDRs or variable regions of nivolumab. Accordingly, in one embodiment, the antibody comprises CDR1, CDR2, and CDR3 domains of the VH of nivolumab having the sequence set forth in SEQ ID NO: 13, and CDR1, CDR2 and CDR3 domains of the VL of nivolumab having the sequence set forth in SEQ ID NO: 14. In another embodiment, the antibody comprises CDR1, CDR2 and CDR3 domains comprising the sequences set forth in SEQ ID NOs: 15, 16, and 17, respectively, and CDR1, CDR2 and CDR3 domains comprising the sequences set forth in SEQ ID NOs: 18, 19, and 20, respectively.
  • the antibody comprises VH and/or VL regions comprising the amino acid sequences set forth in SEQ ID NO: 13 and/or SEQ ID NO: 14, respectively.
  • the antibody competes for binding with and/or binds to the same epitope on PD-1 as the above-mentioned antibodies.
  • the antibody has at least about 90% variable region amino acid sequence identity with the above-mentioned antibodies (e.g., at least about 90%, 95% or 99% variable region identity with SEQ ID NO: 13 or SEQ ID NO: 14).
  • Anti-CTLA-4 antibodies of the instant invention can bind to an epitope on human
  • CTLA-4 so as to inhibit CTLA-4 from interacting with a human B7 counterreceptor. Because interaction of human CTLA-4 with human B7 transduces a signal leading to inactivation of T-cells bearing the human CTLA-4 receptor, antagonism of the interaction effectively induces, augments or prolongs the activation of T cells bearing the human CTLA-4 receptor, thereby prolonging or augmenting an immune response.
  • Anti-CTLA-4 antibodies are described in U.S. Patent Nos. 5,811,097; 5,855,887; 6,051,227; in PCT Application Publication Nos. WO 01/14424 and WO 00/37504; and in U.S. Patent Publication No. 2002/0039581.
  • An exemplary clinical anti-CTLA-4 antibody is ipilimumab or human monoclonal antibody 10D1 as disclosed in WO 01/14424 and U.S. Patent Application No. 09/644,668.
  • Antibody 10D1 has been administered in single and multiple doses, alone or in combination with a vaccine, chemotherapy, or interleukin-2 to more than 500 patients diagnosed with metastatic melanoma, prostate cancer, lymphoma, renal cell cancer, breast cancer, ovarian cancer, and HIV.
  • Other anti-CTLA-4 antibodies encompassed by the methods of the present invention include, for example, those disclosed in: WO 98/42752; WO 00/37504; U.S. Patent No. 6,207,156; Hurwitz et al. (1998) Proc. Natl. Acad. Sci. USA 95(17): 10067-10071; Camacho ei a/. (2004) J. Clin. Oncology 22(145): Abstract No. 2505 (antibody CP-675206); and Mokyr et al. (1998) Cancer Res. 58:5301-5304.
  • the methods of the instant invention comprise use of an
  • the anti-CTLA-4 antibody that is a human sequence antibody, preferably a monoclonal antibody and in another embodiment is monoclonal antibody 10D1.
  • the anti-CTLA-4 antibody binds to human CTLA-4 with a KD of 5 x 10 "8 M or less, binds to human CTLA-4 with a KD of 1 x 10 "8 M or less, binds to human CTLA-4 with a KD of 5 x 10 "9 M or less, or binds to human CTLA-4 with a KD of between 1 x 10 "8 M and 1 x 10 "10 M or less.
  • compositions of CK2 inhibitors of Formulas (I) and (II) useful in the treatment of cancer comprising the administration of a therapeutically effective amount of the compositions of this invention, with or without pharmaceutically acceptable carriers or diluents.
  • a “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • “Pharmaceutically acceptable” means approved by a government regulatory agency or listed in the U.S. Pharmacopeia or another generally recognized pharmacopeia for use in animals, particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered.
  • compositions of this invention comprise at least a compound of Formulas (I) and (II) and a pharmaceutically acceptable carrier.
  • the compositions of the present invention may further comprise one or more
  • additional ingredient(s) such as alum, stabilizers, antimicrobial agents, buffers, coloring agents, flavoring agents, adjuvants, and the like.
  • the compounds of Formulas (I) and (II) and the compositions of the present invention may be administered orally or parenterally including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
  • the compounds of Formulas (I) and (II) may be administered, for example, in the form of tablets or capsules, powders, dispersible granules, or cachets, or as aqueous solutions or suspensions.
  • carriers which are commonly used include lactose, com starch, magnesium carbonate, talc, and sugar, and lubricating agents such as magnesium stearate are commonly added.
  • useful carriers include lactose, corn starch, magnesium carbonate, talc, and sugar.
  • emulsifying and/or suspending agents are commonly added.
  • sweetening and/or flavoring agents may be added to the oral compositions.
  • sterile solutions of the active ingredient(s) are usually employed, and the pH of the solutions should be suitably adjusted and buffered.
  • the total concentration of the solute(s) should be controlled in order to render the preparation isotonic.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously in the wax, for example by stirring.
  • the molten is first melted, and the active ingredient is dispersed homogeneously in the wax, for example by stirring.
  • the molten is first melted, and the active ingredient is dispersed homogeneously in the wax, for example by stirring.
  • homogeneous mixture is then poured into conveniently sized molds and allowed to cool and thereby solidify.
  • Liquid preparations include solutions, suspensions and emulsions. Such preparations are exemplified by water or water/propylene glycol solutions for parenteral injection. Liquid preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas.
  • a pharmaceutically acceptable carrier such as an inert compressed gas.
  • solid preparations which are intended for conversion, shortly before use, to liquid preparations for either oral or parenteral administration.
  • liquid forms include solutions, suspensions and emulsions.
  • the compounds of Formulas (I) and (II) may also be delivered transdermally.
  • the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the present invention encompasses pharmaceutical compositions of anti-PD-1 antibodies or anti-CTLA4 antibodies useful in the treatment of cancer.
  • pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, glycerol polyethylene glycol ricinoleate, and the like.
  • Water or aqueous solution saline and aqueous dextrose and glycerol solutions may be employed as carriers, particularly for injectable solutions (e.g., comprising an anti-PD-1 antibody).
  • the carrier for a composition containing an Ab is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion).
  • a pharmaceutical composition of the invention may include one or more pharmaceutically acceptable salts, anti-oxidant, aqueous and non-aqueous carriers, and/or adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
  • Liquid compositions for parenteral administration can be formulated for administration by injection or continuous infusion. Routes of administration by injection or infusion include intravenous, intraperitoneal, intramuscular, intrathecal and subcutaneous. In one embodiment, the anti-CTLA4 antibody or the anti-PD-1 antibody are administered intravenously.
  • the clinician may utilize preferred dosages as warranted by the condition of the patient being treated.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small amounts until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. Intermittent therapy (e.g. , one week out of three weeks or three out of four weeks) may also be used.
  • the present invention provides combination therapies involving administration of a CK2 inhibitor and an ICM to treat subjects having cancer (e.g., a solid tumor or a B cell lymphoma).
  • a CK2 inhibitor and an ICM will depend upon the diagnosis of the attending physicians and their judgment of the condition of the patient and the appropriate treatment protocol.
  • the CK2 inhibitor is a compound of Formulas (I) and (II) and the ICM is an anti-PD-1 antibody, e.g., nivolumab or anti-CTLA4 antibody, e.g., ipilimumab.
  • the present invention is based, in part, on the following experimental data.
  • Mouse tumor models (MC38 colon carcinoma and 4T1 breast carcinoma) were used to examine the in vivo effect of treating a tumor by combining a CK2 inhibitor of Formulas
  • immunotherapeutic combination was provided either simultaneous with the implant of tumor cells or after the tumor cells were implanted for a time sufficient to become an established tumor. Regardless of the timing of antibody treatment, it was found that CK2 treatment alone, anti-CTLA-4 treatment alone, or anti-PD-1 treatment alone had a modest effect on reducing tumor growth in the MC38 tumor. Nonetheless, the combination treatment of a CK2 inhibitor, i.e., Compound 1, and an anti-CTLA-4 antibody or an anti-PD-1 antibody showed an unexpected, significantly greater effect on reducing tumor growth as compared to treatment with either the CK2 inhibitor, or the anti-CTLA-4 antibody/anti-PD-1 antibody alone ⁇ see, e.g., Tables 1 and 2).
  • a CK2 inhibitor i.e., Compound 1
  • an anti-CTLA-4 antibody or an anti-PD-1 antibody showed an unexpected, significantly greater effect on reducing tumor growth as compared to treatment with either the CK2 inhibitor, or the anti-CTLA-4 antibody/anti-PD-1 antibody alone ⁇
  • the present invention provides a method for treating a hyperproliferative disease, comprising administering a CK2 inhibitor of Formulas (I) and
  • the anti-PD-1 antibody or the anti-CTLA-4 antibody is administered at a subtherapeutic dose.
  • the present invention provides a method for altering an adverse event associated with treatment of a hyperproliferative disease, comprising administering a CK2 inhibitor of Formulas (I) and (II) and a subtherapeutic dose of anti-CTLA-4 antibody to a subject.
  • the present invention provides a method for altering an adverse event associated with treatment of a hyperproliferative disease, comprising administering a CK2 inhibitor of Formulas (I) and (II) and a subtherapeutic dose of anti-PD-1 antibody to a subject.
  • the subject is human.
  • the anti-CTLA-4 antibody is ipilimumab or human sequence monoclonal antibody 10D1 and the anti-PD-1 antibody is nivolumab or human sequence monoclonal antibody, such as 17D8, 2D3, 4H1, 5C4 and 4A11.
  • Human sequence monoclonal antibodies 17D8, 2D3, 4H1, 5C4 and 4A11 have been isolated and structurally characterized, as described in U.S. Provisional Patent No. 60/679,466 (WO 2006/121,168).
  • the anti-CTLA-4 antibody and anti-PD-1 monoclonal antibodies (mAbs) and the human sequence antibodies of the invention can be produced by a variety of techniques, including conventional monoclonal antibody methodology, e.g., the standard somatic cell hybridization technique of Kohler and Milstein (1975) Nature 256:495. Any technique for producing monoclonal antibody can be employed, e.g. , viral or oncogenic
  • hybridomas transformation of B lymphocytes.
  • One animal system for preparing hybridomas is the murine system.
  • Hybridoma production in the mouse is a very well-established procedure.
  • Immunization protocols and techniques for isolation of immunized splenocytes for fusion are known in the art.
  • Fusion partners e.g. , murine myeloma cells
  • fusion procedures are also known (see, e.g. , Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor New York).
  • CK2 inhibitors of Formulas (I) and (II) and anti-PD-1 or anti- CTLA-4 antibodies is useful for enhancement of an immune response against a hyperproliferative disease by both inhibition of CK2 and blockade of PD-1 and CTLA-4.
  • the antibodies of the present invention are human antibodies.
  • these molecules can be administered to cells in culture, in vitro or ex vivo, or to human subjects, e.g., in vivo, to enhance immunity in a variety of situations.
  • the invention provides a method of modifying an immune response in a subject comprising administering to the subject an anti-CTLA-4 antibody or an anti-PD-1 antibody or an antigen-binding portions thereof, such that the immune response in the subject is modified in addition to a CK2 inhibitor of Formulas (I) and (II).
  • the response is enhanced, stimulated or up-regulated.
  • the instant disclosure provides a method of altering adverse events associated with treatment of a hyperproliferative disease with an immunostimulatory therapeutic agent, comprising administering a subtherapeutic dose of anti-CTLA-4 antibody or anti-PD-1 antibody in addition to a CK2 inhibitor of Formulas (I) and (II) to a subject.
  • Blockade of PD-1 and CTLA-4 by antibodies in addition to CK2 inhibition can enhance the immune response to cancerous cells in the patient.
  • Cancers whose growth may be inhibited using the antibodies of the instant disclosure include cancers typically responsive to immunotherapy.
  • Representative examples of cancers for treatment with the combination therapy of the instant disclosure include melanoma (e.g., metastatic malignant melanoma), renal cancer, prostate cancer, breast cancer, colon cancer and lung cancer.
  • cancers examples include bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia,
  • chemotherapeutic agents such as CK2 inhibitors are known to those skilled in the art. In addition, their administration is described in the standard literature.
  • adjunctive or combined administration includes simultaneous administration of a CK2 compound of Formulas (I) and (II) and the anti-CTLA4 or anti-PD-1 antibodies in the same or different dosage form, or separate administration of the compounds and antibodies (e.g., sequential administration).
  • the CK2 inhibitor of Formulas (I) and (II) and the anti-CTLA4 or anti-PD-1 antibodies can be formulated for separate administration and are administered concurrently or sequentially.
  • a CK2 inhibitor of Formulas (I) and (II) can be administered first followed by (e.g., immediately followed by) the administration of the anti-CTLA4 antibody or anti-PD-1 antibody, or vice versa.
  • the CK2 inhibitor of Formulas (I) and (II) is administered prior to administration of the anti-CTLA4 antibody or anti-PD-1 antibody.
  • the CK2 inhibitor of Formulas (I) and (II) is administered after administration of the anti-CTLA4 antibody or anti-PD-1 antibody.
  • the CK2 inhibitor of Formulas (I) and (II) and the anti-CTLA4 antibody or anti-PD-1 antibody are administered concurrently. Such concurrent or sequential administration preferably results in the CK2 inhibitor of Formulas (I) and (II) and the anti-CTLA4 antibody and anti-PD-1 antibody being simultaneously present in treated patients.
  • the doses of the CK2 inhibitor of Formulas (I) and (II) and the anti-CTLA4 or anti-PD-1 antibody are calculated per body weight, e.g., mg/kg body weight.
  • the doses of the CK2 inhibitor of Formulas (I) and (II) and anti-CTLA4 or anti-PD-1 antibody are varied over time.
  • the CK2 inhibitor of Formulas (I) and (II) and the anti-CTLA4 antibody or anti-PD-1 antibody may be initially administered at a high dose and may be lowered over time.
  • the CK2 inhibitor of Formulas (I) and (II) and the anti-CTLA4 antibody or anti-PD-1 antibody are initially administered at a low dose and increased over time.
  • the amount of the CK2 inhibitors of Formulas (I) and (II) and anti-CTLA4 or anti-PD-1 antibodies administered is constant for each dose. In another embodiment, the amount of the CK2 inhibitor of Formulas (I) and (II) and antibody administered varies with each dose. For example, the maintenance (or follow-on) dose of the antibody can be higher or the same as the loading dose which is first administered. In another embodiment, the maintenance dose of the antibody can be lower or the same as the loading dose.
  • the CK2 inhibitor of Formulas (I) and (II) and the anti- PD-1 antibody or anti-CTLA4 antibody are administered as a first line of treatment (e.g., the initial or first treatment).
  • the CK2 inhibitor of Formulas (I) and (II) and the anti-PD-1 antibody or anti-CTLA4 antibody are administered as a second line of treatment (e.g., after the initial or first treatment, including after relapse and/or where the first treatment has failed).
  • the combination is administered to the subject orally for the CK2 inhibitor and intravenously for the anti-PD-1 antibody or an anti-CTLA-4 antibody.
  • the antibody can be administrated intravenously in an induction phase, followed by a maintenance phase.
  • Dosage and frequency vary depending on the half-life of the antibody in the subject. In general, human Abs show the longest half-life, followed by humanized antibodies, chimeric antibodies, and nonhuman antibodies.
  • the dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, a relatively low dosage is typically
  • a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the patient shows partial or complete amelioration of symptoms of disease. Thereafter, the patient can be administered a prophylactic regime.
  • a composition of the present invention can be administered via one or more routes of administration using one or more of a variety of methods well known in the art.
  • the route and/or mode of administration will vary depending upon the desired results.
  • the CK2 inhibitor of Formulas (I) and (II) and anti-CTLA-4 antibody or anti-PD-1 antibody do not have to be administered in the same pharmaceutical composition, and may, because of different physical and chemical characteristics, have to be administered by different routes.
  • the CK2 inhibitor of Formulas (I) and (II) may be administered orally to generate and maintain good blood levels thereof, while the anti-CTLA-4 antibody or anti-PD-1 antibody may be administered intravenously.
  • the determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition, is well within the knowledge of the skilled clinician.
  • the initial administration can be made according to established protocols known in the art, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the skilled clinician.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being unduly toxic to the patient.
  • the selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • the practicing physician can modify each protocol for the administration of a component of the treatment according to the individual patient's needs, as the treatment proceeds.
  • the anti-PD-1 antibody or is administered at a dose ranging from about 0.1 to 10.0 mg/kg body weight once every 1, 2, 3 or 4 weeks.
  • the anti-PD-1 antibody is administered at a dose of 1 or 3 mg/kg body weight once every 2 weeks.
  • the anti-CTLA4 antibody is administered at a dose ranging from about 1 to 10 mg (equivalent to about 0.01 to 0.1 mg/kg body weight) once every 4 or 8 weeks.
  • the anti-CTLA4 antibody is administered at a dose of 3 or 8 mg (equivalent to about 0.03 or 0.1 mg/kg body weight) once every 4 or 8 weeks.
  • the method comprises at least one treatment cycle (e.g., a treatment cycle consisting of four weeks).
  • the CK2 inhibitor is administered on Days 7-14 and anti-CTLA4 antibody or anti-PD-1 antibody is administered on Days 7, 14, 21 and 28.
  • the CK2 inhibitor is administered prior to administration of the anti-CTLA4 antibody or anti-PD-1 antibody.
  • the CK2 inhibitor is administered after administration of the anti- CTLA4 antibody or anti-PD-1 antibody.
  • the treatment cycle can be repeated up to 12 cycles (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 cycles), or as long as a clinical benefit is observed or until there is a complete response, confirmed progressive disease or unmanageable toxicity.
  • Improvement is measured by a reduction in the quantity and/or size of measurable tumor lesions.
  • Size of the tumor can be measured by standard methods such as radiological studies, e.g., CAT or MRI scan and lesions can be measured on chest x-rays or CT or MRI films. Successive measure- ments can be used to judge whether or not growth of the tumor has been retarded or even reversed.
  • cytology or histology can be used to evaluate responsiveness to a therapy.
  • the patient treated exhibits a complete response (CR), a partial response (PR), stable disease (SD), immune-related complete disease (irCR), immune- related partial response (irPR), or immune-related stable disease (irSD).
  • the patient treated experiences tumor shrinkage and/or decrease in growth rate, i.e., suppression of tumor growth.
  • unwanted cell proliferation is reduced or inhibited.
  • one or more of the following can occur: the number of cancer cells can be reduced; tumor size can be reduced; cancer cell infiltration into peripheral organs can be inhibited, retarded, slowed, or stopped; tumor metastasis can be slowed or inhibited; tumor growth can be inhibited; recurrence of tumor can be prevented or delayed; one or more of the symptoms associated with cancer can be relieved to some extent.
  • administering produces at least one therapeutic effect selected from the group consisting of reduction in size of a tumor, reduction in number of metastatic lesions appearing over time, complete remission, partial remission, or stable disease.
  • the improvement of clinical benefit rate is about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or more compared to a CK2 inhibitor, an anti-CTLA4 antibody, or an anti-PD-1 antibody alone.
  • CK2 inhibitors of Formulas (I) and (II) and anti-PD-1 and anti-CTLA-4 antibodies can be further combined with an immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines (He et al. (2004) J. Immunol. 173:4919-28).
  • an immunogenic agent such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines (He et al. (2004) J. Immunol. 173:4919-28).
  • Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gplOO, MAGE antigens, Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF (discussed further below).
  • CK2 inhibitors of Formulas (I) and (II) and anti-PD-1 or anti- CTLA-4 antibodies can be further combined with a vaccination protocol.
  • Many experimental strategies for vaccination against tumors have been devised (see Rosenberg, S. (2000) Development of Cancer Vaccines, ASCO Educational Book Spring: 60-62; Logothetis, C, 2000, ASCO Educational Book Spring: 300-302; Khayat, D. (2000) ASCO Educational Book Spring: 414-428; Foon, K. (2000) ASCO Educational Book Spring: 730-738; see also Restifo and Sznol, Cancer Vaccines, Ch. 61, pp. 3023-3043 in DeVita et al.
  • a vaccine is prepared using autologous or allogeneic tumor cells. These cellular vaccines have been shown to be most effective when the tumor cells are transduced to express GM-CSF. GM-CSF has been shown to be a potent activator of antigen presentation for tumor vaccination (Dranoff et al. (1993) Proc. Natl. Acad. Sci U.S.A. 90: 3539-43).
  • tumor specific antigens are differentiation antigens expressed in the tumors and in the cell from which the tumor arose, for example melanocyte antigens gplOO, MAGE antigens, and Trp-2. More importantly, many of these antigens can be shown to be the targets of tumor specific T cells found in the host.
  • a combined CK2 inhibition and PD-1 or CTLA-4 blockade using the antibody compositions described herein may be used in conjunction with a collection of recombinant proteins and/or peptides expressed in a tumor in order to generate an immune response to these proteins.
  • These proteins are normally viewed by the immune system as self-antigens and are, therefore, tolerant to them.
  • the tumor antigen may also include the protein telomerase, which is required for the synthesis of telomeres of chromosomes and which is expressed in more than 85% of human cancers and in only a limited number of somatic tissues (Kim et al. (1994) Science 266: 2011-2013). (These somatic tissues may be protected from immune attack by various means).
  • Tumor antigen may also be "neo-antigens" expressed in cancer cells because of somatic mutations that alter protein sequence or create fusion proteins between two unrelated sequences (i.e., bcr-abl in the Philadelphia chromosome), or idiotype from B cell tumors.
  • tumor vaccines may include the proteins from viruses implicated in human cancers such a Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV).
  • HPV Human Papilloma Viruses
  • HBV Hepatitis Viruses
  • KHSV Kaposi's Herpes Sarcoma Virus
  • Another form of tumor specific antigen which may be used in conjunction with PD-1 blockade is purified heat shock proteins (HSP) isolated from the tumor tissue itself. These heat shock proteins contain fragments of proteins from the tumor cells and these HSPs are highly efficient at delivery to antigen presenting cells for eliciting tumor immunity (Suot & Srivastava (1995) Science
  • DCs Dendritic cells
  • DCs are potent antigen presenting cells that can be used to prime antigen-specific responses.
  • DCs can be produced ex vivo and loaded with various protein and peptide antigens as well as tumor cell extracts (Nestle et al. (1998) Nature Medicine 4: 328-332).
  • DCs may also be transduced by genetic means to express these tumor antigens as well.
  • DCs have also been fused directly to tumor cells for the purposes of immunization (Kugler et al. (2000) Nature Medicine 6:332-336).
  • DC immunization may be effectively further combined with a combined PD-1 and CTLA-4 blockade to activate more potent anti-tumor responses.
  • CK2 inhibitors of Formulas (I) and (II) and anti-PD-1 or anti- CTLA-4 antibodies may also be further combined with standard cancer treatments. For example, it may be effectively combined with chemotherapeutic regimes. In these instances, it may be possible to reduce the dose of other chemotherapeutic reagent administered with the combination of the instant disclosure (Mokyr et al. (1998) Cancer Research 58: 5301-5304).
  • the scientific rationale behind the combined use of PD-1 or CTLA-4 blockade with chemotherapy is that cell death, which is a consequence of the cytotoxic action of most chemotherapeutic compounds, should result in increased levels of tumor antigen in the antigen presentation pathway.
  • combination therapies that may result in synergy with a combined CK2 inhibition and PD-1 or CTLA-4 blockade through cell death include radiation, surgery, or hormone deprivation. Each of these protocols creates a source of tumor antigen in the host.
  • Angiogenesis inhibitors may also be combined with a combined CK2 inhibition and PD-1 or CTLA-4 blockade. Inhibition of angiogenesis leads to tumor cell death, which may also be a source of tumor antigen to be fed into host antigen presentation pathways.
  • CK2 inhibitors of Formulas (I) and (II) and anti-PD-1 and anti-CTLA-4 antibodies can be used in conjunction with antineoplastic antibodies, such as Rituxan ® (rituximab), Herceptin ® (trastuzumab), Bexxar ® (tositumomab), Zevalin ® (ibritumomab), Campath ® (alemtuzumab), Lymphocide ® (eprtuzumab), Avastin ® (bevacizumab), and Tarceva ® (erlotinib), and the like.
  • antineoplastic antibodies such as Rituxan ® (rituximab), Herceptin ® (trastuzumab), Bexxar ® (tositumomab), Zevalin ® (ibritumomab), Campath ® (alemtuzumab), Lymphocide ® (eprtuzumab),
  • a treatment of a hyperproliferative disease may include an anti-cancer antibody in combination with CK2 inhibitors of Formulas (I) and (II) and anti-PD-1 or anti-CTLA-4 antibodies, concurrently or sequentially or any combination thereof, which may potentiate an anti-tumor immune responses by the host.
  • Tumors evade host immune surveillance by a large variety of mechanisms. Many of these mechanisms may be overcome by the inactivation of proteins, which are expressed by the tumors and which are immunosuppressive. These include, among others, TGF- ⁇ (Kehrl, J. et al. (1986) J. Exp. Med. 163: 1037-1050), IL-10 (Howard, M. & O'Garra, A. (1992) Immunology Today 13: 198-200), and Fas ligand (Hahne, M. et al. (1996) Science 274: 1363-1365).
  • antibodies to each of these entities may be further combined with a CK2 inhibitor of Formulas (I) and (II) and an anti-PD-1 or anti-CTLA-4 combination to counteract the effects of immunosuppressive agents and favor anti-tumor immune responses by the host.
  • CK2 inhibitor of Formulas (I) and (II) and anti-PD-1 or anti-CTLA-4 antibody combination include molecules on the surface of dendritic cells that activate DC function and antigen presentation.
  • Anti-CD40 antibodies are able to substitute effectively for T cell helper activity (Ridge, J. et al. (1998) Nature 393: 474- 478) and can be used in conjunction with an anti-PD-1 and anti-CTLA-4 combination (Ito, N. et al. (2000) Immunobiology 201 (5) 527-40).
  • Activating antibodies to T cell costimulatory molecules, such as OX-40 Weinberg, A. et al.
  • the invention features any of the aforementioned embodiments, wherein the anti-PD-1 antibody is replaced by, or combined with, an anti-PD-Ll or anti- PD-L2 antibody.
  • organs can exhibit immune-related adverse events following immunostimulatory therapeutic antibody therapy, such as the GI tract (diarrhea and colitis) and the skin (rash and pruritis) after treatment with anti-CTLA-4 antibody.
  • immunostimulatory therapeutic antibody therapy such as the GI tract (diarrhea and colitis) and the skin (rash and pruritis) after treatment with anti-CTLA-4 antibody.
  • non-colonic gastrointestinal immune-related adverse events have also been observed in the esophagus (esophagitis), duodenum (duodenitis), and ileum (ileitis) after anti-CTLA-4 antibody treatment.
  • the present invention provides a method for altering an adverse event associated with treatment of a hyperproliferative disease with an immunostimulatory agent, comprising administering a CK2 inhibitor of Formulas (I) and (II) and a subtherapeutic dose of anti-CTLA-4 antibody to a subject or a CK2 inhibitor of Formulas (I) and (II) and a subtherapeutic dose of anti-PD-1 antibody to a subject.
  • the methods of the present invention provide for a method of reducing the incidence of immunostimulatory therapeutic antibody-induced colitis or diarrhea by administering a non-absorbable steroid to the patient.
  • any patient who will receive an immunostimulatory therapeutic antibody is at risk for developing colitis or diarrhea induced by such an antibody, this entire patient population is suitable for therapy according to the methods of the present invention.
  • steroids have been administered to treat inflammatory bowel disease (IBD) and prevent exacerbations of IBD, they have not been used to prevent (decrease the incidence of) IBD in patients who have not been diagnosed with IBD.
  • IBD inflammatory bowel disease
  • non-absorbable steroid is a non-absorbable steroid
  • the non-absorbable steroid is budesonide.
  • Budesonide is a locally-acting glucocorticosteroid, which is extensively metabolized, primarily by the liver, following oral administration.
  • ENTOCORT EC ® (Astra-Zeneca) is a pH- and time-dependent oral formulation of budesonide developed to optimize drug delivery to the ileum and throughout the colon.
  • ENTOCORT EC ® is approved in the U.S. for the treatment of mild to moderate Crohn's disease involving the ileum and/or ascending colon.
  • the usual oral dosage of ENTOCORT EC ® for the treatment of Crohn's disease is 6 to 9 mg/day.
  • ENTOCORT EC ® is released in the intestines before being absorbed and retained in the gut mucosa.
  • ENTOCORT EC ® is extensively metabolized by the cytochrome P450 system in the liver to metabolites with negligible glucocorticoid activity. Therefore, the bioavailability is low (about 10%).
  • the low bioavailability of budesonide results in an improved therapeutic ratio compared to other glucocorticoids with less extensive first- pass metabolism.
  • Budesonide results in fewer adverse effects, including less
  • hypothalamic-pituitary suppression than systemically-acting corticosteroids.
  • chronic administration of ENTOCORT EC ® can result in systemic glucocorticoid effects such as hypercorticism and adrenal suppression. See PDR 58 th ed. 2004; 608-610.
  • the combination of CK2 inhibitors of Formulas (I) and (II) and anti-PD-1 or anti-CTLA-4 antibodies in conjunction with a non-absorbable steroid can be further combined with a salicylate.
  • Salicylates include 5-ASA agents such as, for example: sulfasalazine (AZULFIDINE ® , Pharmacia & UpJohn); olsalazine (DIPENTUM ® , Pharmacia & UpJohn); balsalazide (COLAZAL ® , Salix Pharmaceuticals, Inc.); and mesalamine (ASACOL ® , Procter & Gamble Pharmaceuticals; PENTASA ® , Shire US; CANASA ® , Axcan Scandipharm, Inc.; ROWASA ® , Solvay).
  • 5-ASA agents such as, for example: sulfasalazine (AZULFIDINE ® , Pharmacia & UpJohn); olsalazine (
  • a salicylate administered in combination with CK2 inhibitors of Formulas (I) and (II) and anti-PD-1 or
  • anti-CTLA-4 antibodies and a non-absorbable steroid can includes any overlapping or sequential administration of the salicylate and the non-absorbable steroid for the purpose of decreasing the incidence of colitis induced by the immunostimulatory antibodies.
  • methods for reducing the incidence of colitis induced by the immunostimulatory antibodies according to the present invention encompass
  • a salicylate and a non-absorbable concurrently or sequentially e.g., a salicylate is administered 6 hours after a non-absorbable steroid
  • a salicylate and a non-absorbable steroid can be administered by the same route (e.g., both are administered orally) or by different routes (e.g., a salicylate is administered orally and a non-absorbable steroid is administered rectally), which may differ from the route(s) used to administer the anti- PD-1 or anti-CTLA-4 antibodies.
  • agents used in the modulation of tumor growth or metastasis in a clinical setting such as antiemetics, can also be administered as desired.
  • combinations of the instant invention may also be co-administered with other well-known therapeutic agents that are selected for their particular usefulness against the condition that is being treated.
  • Combinations of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a multiple combination formulation is inappropriate.
  • kits which include a pharmaceutical composition containing a CK2 inhibitor such the compounds of Formulas (I) and (II) and an ICM such as the anti-CTLA4 antibody or an anti-PD-1 antibody, and a pharmaceutically-acceptable carrier, in a therapeutically effective amount adapted for use in the preceding methods.
  • the kits optionally can also include instructions, e.g., comprising administration schedules, to allow a practitioner (e.g., a physician, nurse, or patient) to administer the composition contained therein to administer the composition to a patient having a cancer (e.g., a solid tumor or B cell lymphoma).
  • the kit can also include a syringe.
  • kits include multiple packages of the single-dose pharmaceutical compositions each containing an effective amount of the CK2 inhibitor and the anti- CTLA4 antibody or the anti-PD-1 antibody in accordance with the methods provided above.
  • Instruments or devices necessary for administering the pharmaceutical composition(s) also may be included in the kits.
  • a kit may provide an amount of a CK2 inhibitor as tablets and one or more pre-filled syringes containing an amount of the anti-CTLA4 antibody or the anti-PD-1 antibody.
  • the present invention provides a kit for treating a cancer (e.g., a solid tumor or B cell lymphoma) in a human patient, the kit comprising: (a) a dosage ranging from 0.1 to 50 mg/kg body weight of a CK2 inhibitor (b) a dosage ranging from 1 to 10 mg of an anti-CTLA4 antibody (e.g., ipilimumab) or an anti-PD-1 antibody (e.g., nivolumab) or an antigen-binding portion thereof; and (c) instructions for using the anti- PD-1 antibody and the anti-CTLA4 antibody in a method of the present invention.
  • a cancer e.g., a solid tumor or B cell lymphoma
  • a CK2 inhibitor e.g., a dosage ranging from 1 to 10 mg of an anti-CTLA4 antibody (e.g., ipilimumab) or an anti-PD-1 antibody (e.g., nivolumab)
  • the dosage of the CK2 inhibitor of the kit is 1 to 25 mg/kg body weight and the dosage of the anti-PD-1 antibody is 1 or 3 mg/kg body weight. In certain specific embodiments, In certain specific embodiments, the dosage of the CK2 inhibitor of the kit is 1 to 25 mg/kg body weight and the dosage of the anti-CTLA4 antibody of the kit is 3 or 8 mg.
  • Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo. Nat Immunol. 2015 Mar;16(3):267-75). These results, along with others, led us to the hypothesis that pharmacologic inhibition of CK2 would alter the immune microenvironment in cancers rendering them more sensitive to treatment immunotherapeutic anti-cancer agents such as anti-PD-1 and anti-CTLA-4 monoclonal antibodies. Thus, there was an interest in determining whether a potentiation of an antitumor immune response could be achieved by the combination of a CK2 inhibitor and either a CTLA-4 or PD-1 blocking mAb.
  • mice (strains: C57BL6 for MC38 and BalbC for 4T1) between the ages of 6 and 8 weeks were injected subcutaneously with 1.Ox 10 6 cells in 0.2 mL Hanks Balanced Salt Solution. Seven days post implant; mice were sorted into 6 groups of 8 mice with a mean tumor volume of - 110mm3. Treatments are administered with antibodies and/or CK2 inhibitor at the doses and schedules described in Tables 1 and 2.
  • CTLA-4 and PD-1 antibodies were formulated in Phosphate Buffered Saline (PBS) solution and were administered by intraperitoneal injection.
  • PBS Phosphate Buffered Saline
  • the CK2 inhibitor was formulated in 80% PEG-300, 10% TPGS and 10% Ethanol and was administered by oral gavage.
  • the mice were monitored twice weekly for tumor growth for approximately 6 weeks. Using an electronic caliper, the tumors were measured three dimensionally (height x width x length) and tumor volume was calculated. Mice were euthanized when the tumors reached 1500 mm 3 or when mice showed greater than 15% body weight loss. Measures of antitumor activity included; average % Tumor Growth Inhibition (%TGI), time of tumor progression to target size (T-C), Partial Response (PR) and complete response (CR).
  • %TGI Average % Tumor Growth Inhibition
  • T-C time of tumor progression to target size
  • PR Partial Response
  • CR complete response
  • Time of tumor progression to target size (T-C) refers to the time (days) for the median tumor size of control (C) mice to reach target size (1000 mm 3 ) subtracted from the time for median tumor size of treated (T) mice to reach target size (1000 mm 3 ).
  • Partial regression (PR) indicates greater than 50% (but less than 100%) reduction in tumor size since the initiation of treatment. Complete regression indicates 100% reduction in tumor size for at least two measurements.
  • CK2 inhibitor added to costimulatory pathway modulators such as PD-1 or CTLA-4 mAb resulted in synergistic activity supporting the use of CK2 inhibitor combinations with immunotherapeutic agents in clinical trials. All the combination regimens were well tolerated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et méthodes qui sont utiles pour le traitement et la prévention de troubles prolifératifs.
PCT/US2016/057584 2015-10-20 2016-10-19 Combinaison d'inhibiteurs de ck2 et de modulateurs de points de contrôle immunitaires pour le traitement du cancer Ceased WO2017070137A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562243841P 2015-10-20 2015-10-20
US62/243,841 2015-10-20

Publications (1)

Publication Number Publication Date
WO2017070137A1 true WO2017070137A1 (fr) 2017-04-27

Family

ID=57211587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/057584 Ceased WO2017070137A1 (fr) 2015-10-20 2016-10-19 Combinaison d'inhibiteurs de ck2 et de modulateurs de points de contrôle immunitaires pour le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2017070137A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
CN113015529A (zh) * 2018-10-19 2021-06-22 生华生物科技股份有限公司 用于癌症治疗的免疫调节的组合
CN116211860A (zh) * 2023-05-10 2023-06-06 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170827A2 (fr) * 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2
US20140018319A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Imidazotriazinecarbonitriles useful as kinase inhibitors
WO2015061752A1 (fr) * 2013-10-25 2015-04-30 Pharmacyclics, Inc. Traitement à l'aide d'inhibiteurs de la tyrosine kinase de bruton et de l'immunothérapie

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170827A2 (fr) * 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2
US20140018319A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Imidazotriazinecarbonitriles useful as kinase inhibitors
WO2015061752A1 (fr) * 2013-10-25 2015-04-30 Pharmacyclics, Inc. Traitement à l'aide d'inhibiteurs de la tyrosine kinase de bruton et de l'immunothérapie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TERESA KIM ET AL: "Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma", CANCER BIOLOGY & MEDICINE, TIANJIN YIKE DAXUE FUSHU ZHONGLIU YIYUAN,TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL, CN, vol. 11, no. 4, 1 December 2014 (2014-12-01), pages 237 - 246, XP002759549, ISSN: 2095-3941, DOI: 10.7497/J.ISSN.2095-3941.2014.04.002 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
CN113015529A (zh) * 2018-10-19 2021-06-22 生华生物科技股份有限公司 用于癌症治疗的免疫调节的组合
JP2022508935A (ja) * 2018-10-19 2022-01-19 センワ バイオサイエンシズ，インコーポレイティッド がん治療における免疫モジュレーションのための組合せ
EP3866804A4 (fr) * 2018-10-19 2022-08-03 Senhwa Biosciences, Inc. Combinaisons pour modulation immunitaire dans le traitement du cancer
US12116363B2 (en) * 2018-10-19 2024-10-15 Senhwa Biosciences, Inc. Combinations for immune-modulation in cancer treatment
JP2024147816A (ja) * 2018-10-19 2024-10-16 センワ バイオサイエンシズ，インコーポレイティッド がん治療における免疫モジュレーションのための組合せ
AU2019362050B2 (en) * 2018-10-19 2024-11-07 Senhwa Biosciences, Inc. Combinations for immune-modulation in cancer treatment
IL282294B2 (en) * 2018-10-19 2025-04-01 Senhwa Biosciences Inc Combinations for immune modulation in cancer treatment
CN116211860A (zh) * 2023-05-10 2023-06-06 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物
CN116211860B (zh) * 2023-05-10 2023-08-22 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物

Similar Documents

Publication Publication Date Title
US20220098302A1 (en) Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
US8475790B2 (en) Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
JP2023085370A (ja) 免疫調節剤を併用するがんの治療
JP7393384B2 (ja) がん治療で使用するためのチェックポイント阻害剤及び全細胞マイコバクテリウム
Rini Future approaches in immunotherapy
WO2016029073A2 (fr) Traitement du cancer à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un anticorps anti-cd137
WO2022166909A1 (fr) Utilisation d'un inhibiteur de ppar-delta en combinaison avec un médicament immunothérapeutique pour la préparation d'un médicament antitumoral
CN109195988A (zh) 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
WO2017070137A1 (fr) Combinaison d'inhibiteurs de ck2 et de modulateurs de points de contrôle immunitaires pour le traitement du cancer
US20170355768A1 (en) Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
US20210154183A1 (en) Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
CN113316449A (zh) 胍那苄作为免疫疗法的佐剂
CN117603360A (zh) 用于治疗癌症的多特异性抗体
US20210277135A1 (en) Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
WO2021231346A1 (fr) Dosage et administration d'anticorps anti-ctla -4 activable
CN103768596A (zh) 用于肿瘤治疗的组合产品、其用途及相关方法
Zhang et al. Commentary: Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16788617

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16788617

Country of ref document: EP

Kind code of ref document: A1